Inflammatory Bowel Diseases

Papers
(The TQCC of Inflammatory Bowel Diseases is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
EFFECTS OF DELAYED ENDOSCOPIES IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC131
Multifocal Pyoderma Gangrenosum at Presentation in a Patient With Acute Severe Ulcerative Colitis68
Squamous Cell Carcinoma of the Pouch65
Multisegmental Hypoganglionosis: A Rare Cause of Recurrent Bowel Obstruction and Intestinal Ulcers57
Secondary Indicators for an Evaluation and Guidance System for Quality of Care in Inflammatory Bowel Disease Centers: A Critical Review of the Inflammatory Bowel Disease Quality of Care Center55
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED 53
Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn’s Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared51
Following Through: The Impact of Culinary Medicine on Mediterranean Diet Uptake in Inflammatory Bowel Disease44
Unilateral Painless Vulval Swelling Presenting as an Adverse Reaction to Adalimumab43
Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN40
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis40
Phosphoproteomics Reveals Novel Insights into the Pathogenesis and Identifies New Therapeutic Kinase Targets of Ulcerative Colitis40
Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes38
INCREASE IN MK2 ACTIVITY IN CROHN’S DISEASE: ROLE IN THE INFLAMMATORY ACTIVATION OF FIBROBLASTS38
Is it a Flare? Acute Appendicitis in Ulcerative Colitis Patient Found on Routine Screening Colonoscopy38
Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases37
MATRIX METALLOPROTEINASE (MMP-9) INDUCED INCREASE IN INTESTINAL EPITHELIAL TIGHT JUNCTION BARRIER IS MEDIATED BY EGFR ACTIVATION36
INFLAMMATORY BOWEL DISEASE IN YOUTH UNDER 20 FROM 1990-2019: A GLOBAL PERSPECTIVE ON REGIONAL AND NATIONAL VARIATIONS FROM THE GBD 2019 ANALYSIS36
THE CROHN’S AND COLITIS DISTRESS SCALE: ASSESSING THE DOMAINS OF IMPACT IN YOUTH WITH IBD35
Correction to: Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease35
LONG TERM ADVERSE HEALTH OUTCOMES IN OFFSPRING FROM MOTHERS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION BASED STUDY IN KOREA34
DEPRESSION MAY BE A STRONGER UNIQUE PREDICTOR OF FATIGUE THAN SELF-REPORTED IBD DISEASE ACTIVITY33
IDENTIFYING THE ROLE OF ACINETOBACTER CALCOACETICUS IN DRIVING INTESTINAL INFLAMMATION32
EPITHELIAL MITOCHONDRIAL DYSFUNCTION IN CHRONIC POUCHITIS31
GROUP 3 INNATE LYMPHOID CELLS RELY ON ER STRESS RESPONSE FOR CYTOKINE PRODUCTION IN IBD30
GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS30
LOWER MORTALITY RISK WITH COMBINATION THERAPY WITH ANTI-TNF THERAPY AND THRIOPURINE COMPARED TO THIOPURINE ALONE IN ELDERLY PATIENTS WITH UC29
NOVEL FUNCTION OF MYELOID METHYLTRANSFERASE SMYD5 IN INFLAMMATORY BOWEL DISEASE PROGRESSION29
ARTHRITIS AND ARTHRALGIA AS EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A META-ANALYSIS29
Prior Appendectomy Is Associated With a Milder Clinical Course in Crohn’s Disease: A Nationwide Population-based Cohort Study29
THE ONSET AND SEVERITY OF ULCERATIVE COLITIS IN IL-10 -/- MICE IS NOT DEPENDENT ON FECAL MICROBIOTA TRANSPLANTATION FROM ULCERATIVE COLITIS PATIENTS29
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OL28
COMPARATIVE EFFICACY OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UC PATIENTS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS28
DELAYS IN THE ADMINISTRATION OF BIOLOGIC THERAPIES AND ADVERSE OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY28
Impact of Psychosocial and Neurodevelopmental Disorders on Pediatric Ulcerative Colitis: A Single-Center, Retrospective, Observational Study28
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS28
Pharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease28
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn’s Disease27
Improving Brain–Gut Studies in Crohn’s Disease: Methodological Considerations26
Gut Feelings Matter: The Unresolved Questions of Irritable Bowel Syndrome-Like Symptoms in Inflammatory Bowel Disease in Remission26
Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases26
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry26
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise26
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program25
Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey25
Vitamin D3 andLactobacillus rhamnosusGG/p40 Synergize to Protect Mice From Colitis by Promoting Vitamin D Receptor Expression and Epithelial Proliferation25
Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients: Systematic Review With Meta-Analysis25
Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease24
Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease24
A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses after COVID-19 Vaccination24
SWEET AND SALTY: SWEET SYNDROME AS THE INITIAL PRESENTATION OF NEWLY DIAGNOSED ULCERATIVE COLITIS23
REGIONAL AND RACIAL DISPARITIES IN ULCERATIVE COLITIS AND CHOLANGIOCARCINOMA RELATED MORTALITY IN THE UNITED STATES AND TEXAS: A 21 YEAR OBSERVATIONAL STUDY23
Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Call to Action to Improve Patient Care23
ASSOCIATED COST DIFFERENCES OF SWITCHING BETWEEN INFLIXIMAB PRODUCTS23
PEDIATRIC PATIENTS WITH CORMORBID DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS AND INFLAMMATORY BOWEL DISEASE23
A RARE PRESENTATION OF ULCERATIVE COLITIS WITH ABSCESS FORMATION23
EVIDENCE OF PROTEASE-MEDIATED PRO-NOCICEPTIVE EFFECTS IN INFLAMMATORY BOWEL DISEASE PATIENTS23
AN OBSERVATIONAL STUDY DEMONSTARTING THE MEASUREMENT, CHARACTERIZATION AND VALIDATION OF EXPRESSIONS OF CALPROTECTIN IN HUMAN SWEAT THROUGH A SWEAT WEARABLE22
DO PROVIDERS FAIL TO RECOGNIZE ANXIETY IN SOCIALLY VULNERABLE PATIENTS WITH INFLAMMATORY BOWEL DISEASE?22
Correction to: Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn’s Disease: Determinants of Higher Adherence and Response22
PLIN2 IS AN ARYL HYDROCARBON RECEPTOR TRANSCRIPTIONAL TARGET AND MAY CONTRIBUTE TO MUCOSAL RESTITUTION22
POTENTIAL EFFECTS OF FOOD ON A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER A THERAPEUTIC COMPOUND IN THE COLON22
INCORPORATION OF RISK ASSESSMENT TOOL IMPACTS PATIENT AND GASTROENTEROLOGIST CONFIDENCE AND TREATMENT DECISION MAKING IN BIONAIVE CROHN’S DISEASE22
Childhood Socioeconomic Characteristics and Risk of Inflammatory Bowel Disease: A Scandinavian Birth Cohort Study21
HUMAN β-DEFENSIN 2 ISOFORMS EXPRESSION ON PEDIATRIC IBD21
ULCERATIVE COLITIS-DERIVED INTESTINAL EPITHELIAL CELLS ARE PROTECTED FROM CELL DEATH BY THE IMMUNE MEDIATORS RELEASED FROM RESTING AND ACTIVATED SYSTEMIC T CELLS21
Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis21
HIGH COPY NUMBER POLYMORPHISMS OF ALPHA DEFENSIN 1-3 ARE ASSOCIATED WITH THERAPEUTIC RESPONSIVENESS IN INFLAMMATORY BOWEL DISEASE21
INFECTIOUS COMPLICATIONS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS21
MEDICAL DECISION-MAKING AND EDUCATION RELATED TO OSTOMY SURGERY IN PEDIATRIC PATIENTS WITH IBD: QUALITATIVE THEMES FROM MULTIDISCIPLINARY PROVIDER FOCUS GROUPS21
INCREASED PREVALENCE OF ANXIETY IN HOSPITALIZED CROHN’S DISEASE PATIENTS IN THE UNITED STATES: INSIGHTS FROM NATIONAL INPATIENT DATABASE FROM 2009 TO 201821
TNF IS REQUIRED FOR SPONTANEOUS INNATE COLITIS IN MICE LACKING ADAPTIVE IMMUNITY21
IMPACT OF PATIENT DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND SOCIAL DETERMINANTS OF HEALTH ON ADVANCED THERAPY MEDICATION ADHERENCE AND PERSISTENCE IN ULCERATIVE COLITIS ACROSS UNITED STATES PAYER TY21
Letter: Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis—Authors’ Reply21
Patient Perspectives of Bowel Urgency and Bowel Urgency-Related Accidents in Ulcerative Colitis and Crohn’s Disease20
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study20
FREE AIR FROM WHERE? SPONTANEOUS PNEUMOMEDIASTINUM AND SUBCUTANEOUS EMPHYSEMA IN A PATIENT WITH ULCERATIVE COLITIS IN THE ABSENCE OF COLONIC OR ESOPHAGEAL PERFORATION20
Sarcopenia Is More Prevalent Among Inflammatory Bowel Disease Patients Undergoing Surgery and Predicts Progression to Surgery Among Medically Treated Patients20
Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity20
Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease20
The Norepinephrine-QseC Axis Aggravates F. nucleatum-associated Colitis Through Interkingdom Signaling19
The Selective 5-HT1A Agonist SR57746A Protects Intestinal Epithelial Cells and Enteric Glia Cells and Promotes Mucosal Recovery in Experimental Colitis19
Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients19
The Time to Inflammatory Bowel Disease Diagnosis for Patients Presenting with Abdominal Symptoms in Primary Care and its Association with Emergency Hospital Admissions and Surgery: A Retrospective Coh19
Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study19
MYO5B and the Polygenic Landscape of Very Early-Onset Inflammatory Bowel Disease in an Ethnically Diverse Population19
Challenges in IBD Research 2024: Novel Technologies19
Prevalence of Malnutrition, Its Risk Factors, and the Use of Nutrition Support in Patients with Inflammatory Bowel Disease19
Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes19
REPOGRAMING OF THE INTESTINAL IMMUNE CELL COMPARTMENT DEFINES THE RESPONSE TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN CROHNS DISEASE19
Response to Anti-α4β7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline18
New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry18
Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease18
The Value of a Dedicated IBD Flare Clinic to Effectively Manage Exacerbations of Inflammatory Bowel Disease: The Edinburgh IBD Unit18
Corrigendum to: Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity18
HG-9-91-01 Attenuates Murine Experimental Colitis by Promoting Interleukin-10 Production in Colonic Macrophages Through the SIK/CRTC3 Pathway18
WITHDRAWN: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS18
Antibiotic Use Patterns in the Management of Chronic Pouchitis18
Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process18
Excessive Mitochondrial Fission Suppresses Mucosal Repair by Impairing Butyrate Metabolism in Colonocytes18
Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound18
Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis18
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease18
Epidemiology of Inflammatory Bowel Disease in a Cohort of US Black Women17
Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West17
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials17
Sudden-Onset Polyposis in Pediatric Patients With Ulcerative Colitis17
Intestinal Ultrasound Measures are Strongly Correlated With Small Bowel Endoscopic Lewis Score in Active Crohn’s Disease17
The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis17
Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions17
Microscopic Colitis Is Associated With a Reduced Risk of Colorectal Adenoma and Cancer: A Meta-Analysis17
Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device17
Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients17
AEROMONAS IMMUNE MODULATOR PROTEINS INTERACT WITH HOST LIPOCALIN-2 TO MEDIATE INFLAMMATION THROUGH BOTH HOST- AND MICROBIOME-SPECIFIC MECHANISMS16
EFFICACY AND SAFETY OF VEDOLIZUMAB AND TUMOR NECROSIS FACTOR INHIBITORS IN THE TREATMENT OF STEROID-REFRACTORY MICROSCOPIC COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS16
Current Venous Thromboembolism Chemoprophylaxis Practices After Surgery for Inflammatory Bowel Diseases16
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib16
Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients16
OXPHOS DRIVES CRYPT FISSIONING REQUIRED FOR HEALING OF IBD ULCERS16
PERIPHERAL BLOOD EXTRACELLULAR VESICLE LIPIDS AS BIOMARKERS FOR HUMAN INFLAMMATORY BOWEL DISEASE16
FECAL CALPROTECTIN TESTING: AN INVESTIGATION OF PATIENT COMPLIANCE AND PERCEPTIONS16
SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease—Fear and Desire16
Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey16
Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series16
2ʹ-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT316
THE IMPACT OF INFLAMMATORY BOWEL DISEASES ON THE OUTCOMES OF PATIENTS ADMITTED WITH ACUTE VIRAL HEPATITIS: A 2016-2019 NATIONWIDE ANALYSIS16
Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD16
Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab16
Endoscopic Stenting in Crohn’s Disease-related Strictures: A Systematic Review and Meta-analysis of Outcomes16
THE ROLE OF ALCOHOL USE IN THE DEVELOPMENT OF CROHN’S DISEASE COMPLICATIONS: A RETROSPECTIVE ANALYSIS15
SELF-RATED HEALTH IN INFLAMMATORY BOWEL DISEASE CORRELATES WITH ANXIETY, DEPRESSION, CATASTROPHIC THINKING, AND DISEASE SEVERITY15
Pro-inflammatory Cytokines Promote the Occurrence and Development of Colitis-associated Colorectal Cancer by Inhibiting miR-615-5p15
EICOSATETRAYNOIC ACID REGULATES MITOCHONDRIAL AND EXTRA-CELLULAR MATRIX GENE EXPRESSION AND TISSUE STIFFNESS IN A HUMAN INTESTINAL ORGANOID MODEL OF ILEAL CROHN’S DISEASE15
Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease15
Comment on: “The Burden of Psychiatric Manifestations in Inflammatory Bowel Diseases: A Systematic Review With Meta-analysis”15
ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND HIDRADENITIS SUPPURATIVA: A SINGLE-CENTER RETROSPECTIVE STUDY15
Artificial Intelligence Program to Predict p53 Mutations in Ulcerative Colitis–Associated Cancer or Dysplasia15
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE15
Impact of Inflammatory Bowel Disease on Patients’ Caregivers: Results From a French Survey15
MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL U.S. COHORT15
BEYOND THE BOWEL: A CASE OF SWEET SYNDROME COMPLICATING IBD15
Histologic Predictors of Clinical Outcomes and Healthcare Utilization in Patients With Ileal Pouch-Anal Anastomosis15
MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE15
IMPACT OF TIMING OF INITIATION OF INFLIXIMAB ON THE RISK OF IBD-RELATED SURGERY AND COMPLICATIONS15
How to Minimize Placebo Response and Remission Rates15
Aeroallergen-related Diseases Predate the Diagnosis of Inflammatory Bowel Disease14
Advancing Toward Transmural Healing in Pediatric Crohn’s Disease14
Evaluating lleal Pouch Anal Anastomosis Function: Time to Expand Our ARM-amentarium14
Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present?14
Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria14
CLINICAL BENEFITS OF PROBIOTIC SUPPLEMENTATION IN INFLAMMATORY BOWEL DISEASE TREATMENT: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS14
Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis14
CYTOKINE MULTI-OMICS AND MACHINE LEARNING IDENTIFY MIP1ALPHA AS A NOVEL MEDIATOR IN INFLAMMATORY BOWEL DISEASE14
IBD Journal Editorial Fellowship: A Practical Guide for Future Fellows14
Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients14
EFFICACY OF UPADACITINIB INDUCTION FOR PEDIATRIC IBD14
Top-down Versus Step-up Strategies to Prevent Postoperative Recurrence in Crohn’s Disease14
Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases14
Research Progress of Interleukin-27 in Inflammatory Bowel Disease14
CELLULAR AND MOLECULAR IMPACT OF THE MELANOCORTIN RECEPTOR AGONIST PL8177 IN DEXTRAN SODIUM SULFATE (DSS)-INDUCED COLITIS IN RATS13
BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB13
Coronary Artery Plaque Assessment by CT Angiogram in Inflammatory Bowel Disease13
Association Between Maternal Infections in Pregnancy and the Risk of Inflammatory Bowel Disease in the Offspring: Findings From Two Scandinavian Birth Cohorts13
Use of Upadacitinib as Salvage Therapy for Ulcerative Colitis in Pregnancy: A Case Report13
One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Stu13
PRIMARY EOSINOPHILIC COLITIS WITH CONCOMITANT NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE – A DIAGNOSITIC CONUNDRUM13
MICROBIAL DRIVERS OF REGION-SPECIFIC SUSCEPTIBILITY TO CHRONIC, TNF-INDUCED INTESTINAL INFLAMMATION13
REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN THE UNITED STATES OF AMERICA13
PRELIMINARY EVIDENCE FOR A RELATIONSHIP BETWEEN HEART RATE VARIABILITY AND FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)13
Deep Dive Into MicroRNAs in Inflammatory Bowel Disease13
Colon Cancer in Ulcerative Colitis: A Mimicker of a Flare of Disease13
Insight into Inflammatory Bowel Disease Pathogenesis: Is the Answer Blowing in the Wind?13
The Clinical Interpretation of Cluster Trials13
HISTOPATHOLOGICAL CHARACTERIZATION OF A CHRONIC DSS-INDUCED MOUSE MODEL OF IBD WITH INTESTINAL FIBROSIS13
IDENTIFICATION OF DISEASE SEVERITY DEFINITIONS FOR ULCERATIVE COLITIS AND CROHN’S DISEASE13
EFFICACY OF LOW DOSE NALTREXONE IN PATIENTS WITH CROHN’S COLITIS AND ILEITIS13
VALIDATION OF THE SIMPLIFIED ENDOSCOPIC MUCOSAL ASSESSMENT OF CROHN’S DISEASE (SEMA-CD) A NOVEL ENDPOINT TO ASSESS ENDOSCOPIC IMPROVEMENT WITH REAL WORLD DATA13
Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease13
Potential Utility of Laser Speckle Contrast Imaging to Detect Early Microcirculatory Changes Associated With Erythema Nodosum in Crohn’s Disease: A Case Report13
Fistula Healing Is Low After Fecal Diversion Surgery in Perianal Crohn’s Disease13
An Atlas Characterizing the Shared Genetic Architecture of Inflammatory Bowel Disease with Clinical and Behavioral Traits13
Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized13
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics12
Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study12
Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease12
Patient Portal Usage: An Objective Target for Transition Interventions Among Youth with IBD?12
Single Nucleotide Polymorphisms of the MEFV Gene E148Q Are Highly Associated With Disease Phenotype in Crohn’s Disease12
Preterm Birth and in Utero Exposure to Corticosteroids Are Associated With Increased Infection Risk in Children of Mothers With IBD12
Targeting NCAPD2 as a Therapeutic Strategy for Crohn’s Disease: Implications for Autophagy and Inflammation12
Editorial: Racial Difference in Efficacy of Golimumab in Ulcerative Colitis12
Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom Over the Last 10 Years12
Reply: On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease12
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study12
Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis12
Correction to: Risankizumab Is Effective for the Management of Crohn’s Disease of the Pouch11
THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS11
Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT311
Single-cell Expression Atlas Reveals Cell Heterogeneity in the Creeping Fat of Crohn’s Disease11
ALTERATIONS IN THE MUCOSA-ASSOCIATED MICROBIOME CONTRIBUTE TO THE SEVERITY OF INFLAMMATION IN A DSS-INDUCED COLITIS MODEL11
The Role of Appendicectomy in Ulcerative Colitis: Systematic Review and Meta-Analysis11
Enhancing the Rigor of Research on Herpes Zoster Risk in Patients with IBD Post-SARS-CoV2: Recommendations for Global and Detailed Analyses11
Reply: Plant-Based Diet Recommended for Inflammatory Bowel Disease11
Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis11
Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials11
INFLAMMATORY BOWEL DISEASE IN THE MEDICARE POPULATION: AN ASSESSMENT OF OUTCOMES AND RISK FACTORS IN THE APPALACHIAN REGION11
Deep Sequencing of Crohn’s Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression11
MY SCD PROTOCOL - AN ONLINE, COMPREHENSIVE, REMOTELY-SUPERVISED PROTOCOL FOR IBD PATIENTS TO IMPLEMENT AN EFFECTIVE DIETARY INTERVENTION11
Plant-Based Diet Recommended for Inflammatory Bowel Disease11
Incidence and Prevalence of Primary Sclerosing Cholangitis: A Meta-analysis of Population-based Studies11
CONFIDENCE IN REMISSION: A KEY CONTRIBUTOR IN DEVELOPING POST-TRAUMATIC GROWTH AND MITIGATING MEDICAL TRAUMA AMONG IBD PATIENTS11
EXPLORING SYMPTOM PROFILES IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE USING LATENT CLASS ANALYSIS11
RARE PRESENTATION OF CROHN’S DISEASE WITH ISOLATED OVARIAN INVOLVEMENT11
Letter to the Editor: Re-Revisiting the Association Between Inflammatory Bowel Disease and Parkinson’s Disease10
Call for Emergency Action to Limit Global Temperature Increases, Restore Biodiversity, and Protect Health10
GENERATION OF HUMAN INTESTINAL ORGANOIDS CONTAINING TISSUE-RESIDENT IMMUNE CELLS10
IRE1α-XBP1 CONTROLS GROUP 3 INNATE LYMPHOID CELLS IN INFLAMMATORY BOWEL DISEASE10
SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES10
Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States10
Estrogen Receptor β Activation Mitigates Colitis-associated Intestinal Fibrosis via Inhibition of TGF-β/Smad and TLR4/MyD88/NF-κB Signaling Pathways10
Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis10
TRENDS IN ADMISSIONS, OUTCOMES AND FINANCIAL BURDEN OFC. DIFFICILE INFECTION RELATED HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS: A NATIONWIDE ANALYSIS10
CELL-AUTONOMOUS HEDGEHOG SIGNALING CONTROLS TH17 DIFFERENTIATION TO DRIVE INTESTINAL INFLAMMATION AND IS A DRUGGABLE TARGET FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE10
Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or VariantHLADQA1*05G>A10
Inflammatory Bowel Disease Risk Variants Are Associated with an Increased Risk of Skin Cancer10
SELECTIVELY IMPROVEMENT OF THE RESPONSE OF IMMUNE CELLS TO OPPORTUNISTIC MICROORGANISMS: AN INNOVATIVE PROPOSAL FOR IBD FROM AN ANCIENT GRAIN10
A QUALITATIVE STUDY EXPLORING MEANINGFUL IMPROVEMENT IN BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS10
TRENDS AND RELATED FACTORS OF QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE10
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis10
Management of Perianal Fistulizing Crohn’s Disease10
Risks of Cardiovascular Events in Patients With Inflammatory Bowel Disease in China: A Retrospective Multicenter Cohort Study10
REAL-WORLD EXPERIENCE WITH TOFACITINIB DOSE DE-ESCALATION IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS10
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study10
Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease10
Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn’s-like Disease of the Pouch10
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease10
ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE10
Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients10
ANALYSIS OF THE GENETIC EXPRESSION OF COLON CANCER GENETIC BIOMARKERS ON INFLAMMATORY BOWEL DISEASE ON BLOOD AND BIOPSY SAMPLES10
Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation10
Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series10
Food-Related Quality of Life in Children and Adolescents With Crohn’s Disease10
QUANTITATIVE AND EXPLAINABLE ARTIFICIAL INTELLIGENCE (AI)-POWERED APPROACHES TO PREDICT ULCERATIVE COLITIS DISEASE ACTIVITY FROM HEMATOXYLIN AND EOSIN (H&E)-STAINED WHOLE SLIDE IMAGES (WSI)10
AUPHOS, A “FIRST-IN CLASS“ ORAL AGENT FOR CORRECTING METABOLIC DYSFUNCTION IN IBD10
Reply to “Patients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccination”10
Obesity, Sarcopenia and Myosteatosis: Impact on Clinical Outcomes in the Operative Management of Crohn’s Disease9
NAD+ DEPLETION IN THE INTESTINAL EPITHELIUM RESULTS IN MITOCHONDRIAL DYSFUNCTION AND INFLUENCES THE PATHOGENESIS OF EXPERIMENTAL COLITIS9
Depression in Women With Inflammatory Bowel Disease: A Multifaceted Approach for a Multidimensional Problem9
SIMPLIFIED INDEX FOR ASSESSING MICROBIAL DIVERSITY OF THE HUMAN DIGESTIVE TRACT IN A CLINICAL SETTING9
Shedding New Light on High-Risk Phenotypes for Pouchitis9
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD9
0.2180380821228